Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-09-05

FDA Approved: MIRVASO — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

The FDA approved a supplemental application for Mirvaso (brimonidine tartrate) from Galderma Laboratories, L.P. This action represents an update to the product'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mirvaso (brimonidine tartrate)

Snippet

SUPPL AP for MIRVASO (BRIMONIDINE TARTRATE)